**UNITED STATES**
**SECURITIES AND EXCHANGE COMMISSION**
**Washington, D.C. 20549**

# FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER**
**PURSUANT TO RULE 13a-16 OR 15d-16**
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of January 2020**

**Commission File Number: 001-38764**

## APTORUM GROUP LIMITED

**17th Floor, Guangdong Investment Tower**
**148 Connaught Road Central**
**Hong Kong**
**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

We are filing this report to disclose a One Pager the Company will use during corporate presentations; such One Pager is incorporated herein by reference.

Neither this report nor the One Pager attached hereto as Exhibit 99.1 constitute an offer to sell, or the solicitation of an offer to buy our securities, nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

The information in this Form 6-K, including Exhibit 99.1 shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

This Form 6-K is hereby incorporated by reference into the registration statements of the Company on Form S-8 (Registration Number 333-232591) and Form F-3 (Registration Number 333-235819) and into each prospectus outstanding under the foregoing registration statements, to the extent not superseded by documents or reports subsequently filed or furnished by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

**EXHIBIT INDEX**

| Exhibit No. | Description |
|---|---|
| 99.1 | Corporate One Pager |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Aptorum Group Limited**

Date: January 13, 2020

By: /s/ Sabrina Khan
Name: Sabrina Khan
Title: Chief Financial Officer

**EXHIBIT INDEX**

| Exhibit No. | Description |
| --- | --- |
| 99.1 | Corporate One Pager |

# APTORUM GROUP - Novel Therapeutics for Unmet Needs

NASDAQ:APM Q4 2019 UPDATES

APTORUM

## SMART-ACT™ (SACT)

### Rare disease universe

| | |
|---|---|
| No. of Rare Diseases | 7,000 & rising |
| FDA-approved Orphan Drugs | 770 |
| Rare Diseases without Treatment | 95% |
| No. of Clinical Trials in Rare Diseases | 600 |
| Market Size (US$bn) | US$ 223bn |
| Total Rare Disease Incidence (US) | 10% |
| Orphan drug sales CAGR (19-24) | 12% |
| Non-orphan drug sales CAGR (19-24) | 6% |

### APTORUM Systematic approach to rare diseases

| | |
|---|---|
| Non-Orphan Avg. Drug Development Cost | US$ 291m |
| SMART-ACT™ Avg. Drug Development Cost | US$ 20-40m |
| SMART-ACT™ Modality | Repurposed small molecule |
| SACT-1 Indication | Neuroblastoma |

## ALS-4 (MRSA bacteremia)

### ALS-4

| | |
|---|---|
| Modality | Small molecule |
| Mechanism | First-in-Class Oral Non-antibiotic |
| Market Size | US$ 4bn (2025) |
| MRSA bacteremia incidence (US) | >130,000 |

### Recent deals in anti-infectives

US$ 8.4bn Merck acq. of Cubist Pharm. (2014)

US$ 658m Roivant licensing of Intron's Ph1 asset (2018)

## Claves (druggable microbiome platform)

| Diseases (70+ indications) | Mkt size |
|---|---|
| 1. Obesity (CLS-1) | US$ 6bn |
| 2. Diabetes | US$ 22bn |
| 3. CV disease | US$ 130bn |
| 4. Renal failure | US$ 93bn |
| 5. Alzheimer's disease | US$ 18bn |

## Market projection (US)

| SACT-1 | 2018A | 2035E |
|---|---|---|
| US Total Population (m) | 328.1 | 363.2 |
| Neuroblastoma | 2,612 | 2,891 |
| of which high-risk | 1,175 | 1,301 |

| ALS-4 | 2018A | 2035E |
|---|---|---|
| MRSA bacteremia | 136,967 | 172,451 |
| MRSA pneumonia | 136,967 | 172,451 |
| MRSA endocarditis | 68,484 | 86,226 |
| MRSA bone & joint infection | 8,950 | 11,269 |
| Immunocompromised patients | 10m+ | 10m+ |

| CLS-1 | 2018A | 2035E |
|---|---|---|
| Obese population (m) | 127.3 | 141 |

## Summary of our assumptions on TAM, price, market share and peak sales

| | Stage | Clin. Ph PoS | Incidence (2020,US) | ASP (USD) | Launch Year | 2024 M/S | 2024 Sales (USDm) | 2030 M/S | 2030 Sales (USDm) |
|---|---|---|---|---|---|---|---|---|---|
| SACT-1 (Neuroblastoma) | (Repurposed) Ph2/3 | 24.6% | 2,612 | 204,900 | 2022 | 25% | 43 | 50% | 111 |
| ALS-4 (MRSA bacteremia) | Preclinical | 69.5% | 136,967 | 14,639 | 2022 | 25% | 284 | 75% | 1,246 |
| CLS-1 (Obesity) | Preclinical | 61.1% | 127,335,000 | 513 | 2024 | 10% | 30 | 20% | 1,030 |
| DOI (Menopause) | Dietary Supplement | n/a | 36,520,000 | 200 | 2020 | 1% | 52 | 5% | 360 |

Current progress of pipeline programs: → Lead Projects → Other Candidates → Projected timeline

Note: all projected timelines refer to the estimated commencement time of the indicated stages

| Program | Indication | Mechanism | Computational Discovery | *In vitro* validation | Existing PhI/II clinical safety data[1] | IND 505(b)(2) filing[2] *In vivo* validation | Bridging studies | PhII / III with limited population[3] |
|---|---|---|---|---|---|---|---|---|
| SACT-1 | Neuroblastoma | Drug Repurposing | | | | Q4 2019 | | ready for clinical trial by Q2/Q3 2020 |
| SACT-2 | To be disclosed | Drug Repurposing | | | | | | |
| SACT-3 | To be disclosed | Drug Repurposing | | | | | | |

| Program | Indication | Mechanism | Discovery | Lead Optimization | IND enabling | Phase I | Phase II / III |
|---|---|---|---|---|---|---|---|
| ALS-4 | Anti *S. aureus* (incl. MRSA) | Anti-virulence | | + oral formulation | Q3 2019 | Q1/2 2020 | based on LPAD pathway[4] |
| CLS-1 | Obesity | Druggable Microbiota | | Q4 2019 | Q2 2020 | Q4 2020 | |

| Program | Modality | Indication | Formulation | Commercialisation |
|---|---|---|---|---|
| DOI (NLS-2) | Dietary Supplement | Menopausal symptoms[5] | | Q1 2020 |

Sources to industry data, market size and financial projections available upon request. For full description of our programs please visit ir.aptorumgroup.com

1. Refers to the drug's existing Phase I/II safety data previously conducted by a third party. Does not refer to clinical trials conducted by Aptorum
2. Subject to FDA's approval on a case-by-case basis, a 505(b)(2) can rely in part on existing information from approved products (such as FDA's previous finding on safety and efficacy) or data in the public domain
3. Subject to the FDA's approval
4. ALS-4's eligibility for the LPAD pathway is subject to the FDA's approval. Targeting other indications in Phase II may affect our valuation. QIDP status can be applied once we identify an indication
5. BBC News: "National shortage in hormone replacement therapy adds to the stress of menopause" Aug 2019

IR CONTACTS T +852 2117 6611 E investor.relations@aptorumgroup.com W ir.aptorumgroup.com